Effect of procaine amide, quinidine, and ajmaline in the Wolff-Parkinson-White syndrome.
D000328:Adult; D000404:Ajmaline / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D006325:Heart Atria / Q000187:drug effects; D006327:Heart Block / Q000139:chemically induced; D006329:Heart Conduction System / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000009:adverse effects / Q000627:therapeutic use*; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use*; D012032:Refractory Period, Electrophysiological / Q000187:drug effects; D013610:Tachycardia / Q000188:drug therapy / Q000517:prevention & control; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy*
D000404:Ajmaline; D011802:Quinidine; D011342:Procainamide